

A non-peptide small molecule GLP-1 receptor agonist built for oral bioavailability — no reconstitution, no needle, no cold chain.
For research use only · not for human consumption
Orders are placed, processed, and shipped by Prime Bio Group. Fresno Peptide Lab does not stock or sell product — we may earn a commission at no extra cost to you.
Orforglipron is an oral, non-peptide small molecule that functions as a selective glucagon-like peptide-1 receptor agonist (GLP-1RA). Unlike traditional peptide-based GLP-1 therapies, Orforglipron is structurally designed for oral bioavailability, eliminating the need for subcutaneous injections. It acts on the GLP-1 receptor to enhance insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite.
In research settings, Orforglipron has been widely studied for its effects on weight management, glycemic control, and metabolic regulation. Early investigations highlight its potential as a once-daily oral GLP-1 agonist, offering improved patient compliance and accessibility compared to injectable options. Potential applications of Orforglipron research include:
Summary of published preclinical and clinical literature, provided for research context only. Not a claim of efficacy and not medical advice.
A non-peptide small molecule GLP-1 receptor agonist built for oral bioavailability — no reconstitution, no needle, no cold chain.
Prime Bio Group supplies Orforglipron as oral. Available options: Single unit at $105.
Yes. Prime Bio Group is a physician-owned lab and provides a certificate of analysis on every batch. A COA reports identity by mass spectrometry and purity by HPLC — if you are not sure how to read one, our guide on reading a certificate of analysis walks through it line by line.